nach oben

Clinical Rheumatology

Erschienen in:

12.06.2020 | Original Article

The circRNA–miRNA–mRNA regulatory network in systemic lupus erythematosus

verfasst von: Junhui Zhang, Yuan Liu, Guixiu Shi

Erschienen in: Clinical Rheumatology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction/objectives

Systemic lupus erythematosus (SLE) was an autoimmune disease with a large variety of clinical manifestations and involving many organs. Its exact etiology was unclear, and studies had shown that T cells may play an important role. In this study, we wished to study the regulatory mechanism of circRNA in the T cells from SLE patients.

Method

GSE84655 was retrieved from the GEO database, and the corresponding probe name was converted into an international standard circRNA name by using the practical extraction and report language. The differentially expressed circRNAs (DECs) were analyzed by using R software. Subsequently, we used multiple bioinformatics methods to obtain the target miRNAs of circRNAs and the downstream mRNAs of miRNAs. Finally, a circRNA–miRNA–mRNA regulatory network was constructed and visualized by using Cytoscape 3.6.1 software.

Results

There were a total of 29 DECs that had been identified, including 2 upregulated circRNAs and 27 downregulated circRNAs. After a lot of in-depth analysis, we finally obtained a circRNA–miRNA–mRNA regulatory network consisting of 8 DECs (hsa_circ_0006770, hsa_circ_0002904, hsa_circ_0034044, hsa_circ_0023685, hsa_circ_0049271, hsa_circ_0074491, hsa_circ_0074559, and hsa_circ_0023461), 4 overlap miRNAs (hsa-miR-326, hsa-miR-569, hsa-miR-638, and hsa-miR-1246), and 13 target mRNAs (EPHB3, USH1G,UBE4A, DCAF7, TBL1XR1, SLC27A4, SMO, NAA30, RSBN1, PLAG1, SOX2, GPATCH11, and DYRK1A).

Conclusions

This study could provide a novel insight into the role of circRNA and the circRNA–miRNA–mRNA regulation network in the SLE. However, it also needed to be verified by subsequent experiments and clinical studies.

Key Points

• There were 29 DECs (2 up and 27 down) between T cells of SLE and health control.

• Hsa-miR-338-3p, hsa-miR-767-3p, and hsa-miR-1827 were the most frequent miRNAs.

• We obtained a circRNA–miRNA–mRNA regulatory network for SLE.

Nur mit Berechtigung zugänglich

Zucchi D, Elefante E, Calabresi E, Signorini V, Bortoluzzi A, Tani C (2019) One year in review 2019: systemic lupus erythematosus. Clin Exp Rheumatol 37(5):715–722PubMed

Nusbaum JS, Mirza I, Shum J, Freilich RW, Cohen RE, Pillinger MH, Izmirly PM, Buyon JP (2020) Sex differences in systemic lupus erythematosus: epidemiology, clinical considerations, and disease pathogenesis. Mayo Clin Proc 95(2):384–394. https://doi.org/10.1016/j.mayocp.2019.09.012CrossRefPubMed

Li LJ, Zhu ZW, Zhao W, Tao SS, Li BZ, Xu SZ, Wang JB, Zhang MY, Wu J, Leng RX, Fan YG, Pan HF, Ye DQ (2018) Circular RNA expression profile and potential function of hsa_circ_0045272 in systemic lupus erythematosus. Immunology 155(1):137–149. https://doi.org/10.1111/imm.12940CrossRefPubMedPubMedCentral

Sharabi A, Tsokos GC (2020) T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat Rev Rheumatol 16(2):100–112. https://doi.org/10.1038/s41584-019-0356-xCrossRefPubMed

Li S, Zhang J, Tan X, Deng J, Li Y, Piao Y, Li C, Yang W, Mo W, Sun J, Sun F, Han T, Wang J, Kuang W, Li C (2019) Microarray expression profile of circular RNAs and mRNAs in children with systemic lupus erythematosus. Clin Rheumatol 38(5):1339–1350. https://doi.org/10.1007/s10067-018-4392-8CrossRefPubMed

Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK (1976) Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A 73(11):3852–3856. https://doi.org/10.1073/pnas.73.11.3852CrossRefPubMedPubMedCentral

Li H, Li K, Lai W, Li X, Wang H, Yang J, Chu S, Wang H, Kang C, Qiu Y (2018) Comprehensive circular RNA profiles in plasma reveals that circular RNAs can be used as novel biomarkers for systemic lupus erythematosus. Clin Chim Acta 480:17–25. https://doi.org/10.1016/j.cca.2018.01.026CrossRefPubMed

Miao Q, Zhong Z, Jiang Z, Lin Y, Ni B, Yang W, Tang J (2019) RNA-seq of circular RNAs identified circPTPN22 as a potential new activity indicator in systemic lupus erythematosus. Lupus 28(4):520–528. https://doi.org/10.1177/0961203319830493CrossRefPubMed

Floris G, Zhang L, Follesa P, Sun T (2017) Regulatory role of circular RNAs and neurological disorders. Mol Neurobiol 54(7):5156–5165. https://doi.org/10.1007/s12035-016-0055-4CrossRefPubMed

10.

Wang L, Shen C, Wang Y, Zou T, Zhu H, Lu X, Li L, Yang B, Chen J, Chen S, Lu X, Gu D (2019) Identification of circular RNA Hsa_circ_0001879 and Hsa_circ_0004104 as novel biomarkers for coronary artery disease. Atherosclerosis 286:88–96. https://doi.org/10.1016/j.atherosclerosis.2019.05.006CrossRefPubMed

11.

Lei M, Zheng G, Ning Q, Zheng J, Dong D (2020) Translation and functional roles of circular RNAs in human cancer. Mol Cancer 19(1):30. https://doi.org/10.1186/s12943-020-1135-7CrossRefPubMedPubMedCentral

12.

Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A (2013) NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res 41(Database issue):D991–D995. https://doi.org/10.1093/nar/gks1193CrossRefPubMed

13.

Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M (2016) CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol 13(1):34–42. https://doi.org/10.1080/15476286.2015.1128065CrossRefPubMed

14.

Huang Z, Shi J, Gao Y, Cui C, Zhang S, Li J, Zhou Y, Cui Q (2019) HMDD v3.0: a database for experimentally supported human microRNA-disease associations. Nucleic Acids Res 47(D1):D1013–D1017. https://doi.org/10.1093/nar/gky1010CrossRefPubMed

15.

Huang HY, Lin YC, Li J, Huang KY, Shrestha S, Hong HC, Tang Y, Chen YG, Jin CN, Yu Y, Xu JT, Li YM, Cai XX, Zhou ZY, Chen XH, Pei YY, Hu L, Su JJ, Cui SD, Wang F, Xie YY, Ding SY, Luo MF, Chou CH, Chang NW, Chen KW, Cheng YH, Wan XH, Hsu WL, Lee TY, Wei FX, Huang HD (2020) miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res 48(D1):D148–D154. https://doi.org/10.1093/nar/gkz896CrossRefPubMed

16.

Agarwal V, Bell GW, Nam JW, Bartel DP (2015) Predicting effective microRNA target sites in mammalian mRNAs. Elife 4. https://doi.org/10.7554/eLife.05005

17.

Chen Y, Wang X (2020) miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res 48(D1):D127–D131. https://doi.org/10.1093/nar/gkz757CrossRefPubMed

18.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498–2504. https://doi.org/10.1101/gr.1239303CrossRefPubMedPubMedCentral

19.

Guo G, Wang H, Ye L, Shi X, Yan K, Lin K, Huang Q, Li B, Lin Q, Zhu L, Xue X, Zhang H (2019) Hsa_circ_0000479 as a novel diagnostic biomarker of systemic lupus erythematosus. Front Immunol 10:2281. https://doi.org/10.3389/fimmu.2019.02281CrossRefPubMedPubMedCentral

20.

Zurawska A, Mycko MP, Selmaj KW (2019) Circular RNAs as a novel layer of regulatory mechanism in multiple sclerosis. J Neuroimmunol 334:576971. https://doi.org/10.1016/j.jneuroim.2019.576971CrossRefPubMed

21.

Wang J, Yan S, Yang J, Lu H, Xu D, Wang Z (2019) Non-coding RNAs in rheumatoid arthritis: from bench to bedside. Front Immunol 10:3129. https://doi.org/10.3389/fimmu.2019.03129CrossRefPubMed

22.

Luo Q, Zhang L, Li X, Fu B, Guo Y, Huang Z, Li J (2019) Identification of circular RNAs hsa_circ_0044235 and hsa_circ_0068367 as novel biomarkers for systemic lupus erythematosus. Int J Mol Med 44(4):1462–1472. https://doi.org/10.3892/ijmm.2019.4302CrossRefPubMedPubMedCentral

23.

Zhang MY, Wang JB, Zhu ZW, Li LJ, Liu RS, Yang XK, Leng RX, Li XM, Pan HF, Ye DQ (2018) Differentially expressed circular RNAs in systemic lupus erythematosus and their clinical significance. Biomed Pharmacother 107:1720–1727. https://doi.org/10.1016/j.biopha.2018.08.161CrossRefPubMed

24.

Xue Q, Sun K, Deng HJ, Lei ST, Dong JQ, Li GX (2014) MicroRNA-338-3p inhibits colorectal carcinoma cell invasion and migration by targeting smoothened. Jpn J Clin Oncol 44(1):13–21. https://doi.org/10.1093/jjco/hyt181CrossRefPubMed

25.

Gao L, Xiong DD, He RQ, Lai ZF, Liu LM, Huang ZG, Yang X, Wu HY, Yang LH, Ma J, Li SH, Lin P, Yang H, Luo DZ, Chen G, Dang YW (2019) Identifying TF-miRNA-mRNA regulatory modules in nitidine chloride treated HCC xenograft of nude mice. Am J Transl Res 11(12):7503–7522PubMedPubMedCentral

26.

Fasihi A, Bahram MS, Atashi A, Nasiri S (2018) Introduction of hsa-miR-103a and hsa-miR-1827 and hsa-miR-137 as new regulators of Wnt signaling pathway and their relation to colorectal carcinoma. J Cell Biochem 119(7):5104–5117. https://doi.org/10.1002/jcb.26357CrossRefPubMed

27.

Alexandri C, Daniel A, Bruylants G, Demeestere I (2020) The role of microRNAs in ovarian function and the transition toward novel therapeutic strategies in fertility preservation: from bench to future clinical application. Hum Reprod Update 26:174–196. https://doi.org/10.1093/humupd/dmz039CrossRefPubMed

28.

Jimenez-Lucena R, Camargo A, Alcala-Diaz JF, Romero-Baldonado C, Luque RM, van Ommen B, Delgado-Lista J, Ordovas JM, Perez-Martinez P, Rangel-Zuniga OA, Lopez-Miranda J (2018) A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study. Exp Mol Med 50(12):168–112. https://doi.org/10.1038/s12276-018-0194-yCrossRefPubMedCentral

29.

Foinquinos A, Batkai S, Genschel C, Viereck J, Rump S, Gyongyosi M, Traxler D, Riesenhuber M, Spannbauer A, Lukovic D, Weber N, Zlabinger K, Hasimbegovic E, Winkler J, Fiedler J, Dangwal S, Fischer M, de la Roche J, Wojciechowski D, Kraft T, Garamvolgyi R, Neitzel S, Chatterjee S, Yin X, Bar C, Mayr M, Xiao K, Thum T (2020) Preclinical development of a miR-132 inhibitor for heart failure treatment. Nat Commun 11(1):633. https://doi.org/10.1038/s41467-020-14349-2CrossRefPubMedPubMedCentral

30.

Salvi V, Gianello V, Tiberio L, Sozzani S, Bosisio D (2019) Cytokine targeting by miRNAs in autoimmune diseases. Front Immunol 10:15. https://doi.org/10.3389/fimmu.2019.00015CrossRefPubMedPubMedCentral

31.

Sharaf-Eldin WE, Kishk NA, Gad YZ, Hassan H, Ali MAM, Zaki MS, Mohamed MR, Essawi ML (2017) Extracellular miR-145, miR-223 and miR-326 expression signature allow for differential diagnosis of immune-mediated neuroinflammatory diseases. J Neurol Sci 383:188–198. https://doi.org/10.1016/j.jns.2017.11.014CrossRefPubMed

32.

Chen JQ, Papp G, Poliska S, Szabo K, Tarr T, Balint BL, Szodoray P, Zeher M (2017) MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjogren’s syndrome. PLoS One 12(3):e0174585. https://doi.org/10.1371/journal.pone.0174585CrossRefPubMedPubMedCentral

33.

Hikami K, Kawasaki A, Ito I, Koga M, Ito S, Hayashi T, Matsumoto I, Tsutsumi A, Kusaoi M, Takasaki Y, Hashimoto H, Arinami T, Sumida T, Tsuchiya N (2011) Association of a functional polymorphism in the 3′-untranslated region of SPI1 with systemic lupus erythematosus. Arthritis Rheum 63(3):755–763. https://doi.org/10.1002/art.30188CrossRefPubMed

34.

Steen SO, Iversen LV, Carlsen AL, Burton M, Nielsen CT, Jacobsen S, Heegaard NH (2015) The circulating cell-free microRNA profile in systemic sclerosis is distinct from both healthy controls and systemic lupus erythematosus. J Rheumatol 42(2):214–221. https://doi.org/10.3899/jrheum.140502CrossRefPubMed

35.

Ishibe Y, Kusaoi M, Murayama G, Nemoto T, Kon T, Ogasawara M, Kempe K, Yamaji K, Tamura N (2018) Changes in the expression of circulating microRNAs in systemic lupus erythematosus patient blood plasma after passing through a plasma adsorption membrane. Ther Apher Dial 22(3):278–289. https://doi.org/10.1111/1744-9987.12695CrossRefPubMed

Titel: The circRNA–miRNA–mRNA regulatory network in systemic lupus erythematosus
verfasst von: Junhui Zhang
Yuan Liu
Guixiu Shi
Publikationsdatum: 12.06.2020
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 1/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05212-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The circRNA–miRNA–mRNA regulatory network in systemic lupus erythematosus

Abstract

Introduction/objectives

Method

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Innere Medizin

Springer Medizin

Abstract

Introduction/objectives

Method

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Challenges of caring for homeless patients with rheumatic and musculoskeletal disorders in Los Angeles

Urinary ferritin creatinine ratio, a potential biomarker for lupus nephritis activity

Effectiveness of platelet-rich plasma in the management of hip osteoarthritis: a systematic review and meta-analysis

Clinical features associated with pregnancy outcomes in women with positive antiphospholipid antibodies and previous adverse pregnancy outcomes: a real-world prospective study

Precision medicine for rheumatologists: lessons from the pharmacogenomics of azathioprine

Presentation of multiple myeloma occurring in the humerus after strain: a case report

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Innere Medizin